Literature DB >> 22864747

Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats.

Renan Qin1, Jianyu Zhang, Chuyuan Li, Xiaoqi Zhang, Aihua Xiong, Feng Huang, Zhen Yin, Kongyan Li, Wenyu Qin, Mingzhen Chen, Shubing Zhang, Lingyi Liang, Huiye Zhang, Hong Nie, Wencai Ye.   

Abstract

In the present study, the protective effects of gypenosides from Gynostemma pentaphyllum on fatty liver disease (FLD) were examined in rats treated with high fat and cholesterol diet and alcohol. Male SD rats were divided into seven groups: control, model, lovastatin, silymarin, gypenosides high-, medium- and low-treatment groups. The latter 6 groups were fed high-fat and cholesterol diet and administered alcohol intragastricly once a day. Body weight was measured every week for 10 weeks, and the hepatic index was measured after 10 weeks. Compared with model group, levels of serum triglyceride (TG), total cholesterol (TC), free fatty acid (FFA), and low density lipoprotein cholesterol (LDL-C) level, malondialdehyde (MDA), serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity, and hepatocyte apoptosis were significantly decreased in gypenosides groups; while serum high density lipoprotein cholesterol (HDL-C), superoxide dismutase (SOD) activity in both serum and hepatic tissue and mRNA and protein level of peroxisome proliferator-activated receptor α (PPAR-α) were significantly increased. Moreover, hepatic steatosis and mitochondrial damage were improved. These results suggested that gypenosides could prevent liver fatty degeneration in fatty liver disease through modulating lipid metabolism, ameliorating liver dysfunction and reducing oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22864747     DOI: 10.1007/s12272-012-0715-5

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  14 in total

1.  Gypenoside attenuates renal ischemia/reperfusion injury in mice by inhibition of ERK signaling.

Authors:  Qifa Ye; Y I Zhu; Shaojun Ye; Hong Liu; Xingguo She; Ying Niu; Yingzi Ming
Journal:  Exp Ther Med       Date:  2016-01-29       Impact factor: 2.447

2.  Metabolomic mechanisms of gypenoside against liver fibrosis in rats: An integrative analysis of proteomics and metabolomics data.

Authors:  Ya-Nan Song; Shu Dong; Bin Wei; Ping Liu; Yong-Yu Zhang; Shi-Bing Su
Journal:  PLoS One       Date:  2017-03-14       Impact factor: 3.240

Review 3.  Anti-cancer effects of Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan).

Authors:  Yantao Li; Wanjun Lin; Jiajun Huang; Ying Xie; Wenzhe Ma
Journal:  Chin Med       Date:  2016-09-27       Impact factor: 5.455

4.  Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats.

Authors:  Shu-Hua Shen; Ting-Yan Zhong; Cui Peng; Jie Fang; Bin Lv
Journal:  BMC Complement Med Ther       Date:  2020-02-05

5.  Gypenoside attenuates hepatic ischemia/reperfusion injury in mice via anti-oxidative and anti-apoptotic bioactivities.

Authors:  Jie Zhao; Yingzi Ming; Qiquan Wan; Shaojun Ye; Song Xie; Yi Zhu; Yanfeng Wang; Zibiao Zhong; Ling Li; Qifa Ye
Journal:  Exp Ther Med       Date:  2014-02-21       Impact factor: 2.447

6.  Metabonomics study of the therapeutic mechanism of Gynostemma pentaphyllum and atorvastatin for hyperlipidemia in rats.

Authors:  Miao Wang; Fei Wang; Yinan Wang; Xiaonan Ma; Min Zhao; Chunjie Zhao
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

7.  Biotransformation of ginsenoside Rb1 via the gypenoside pathway by human gut bacteria.

Authors:  Hong Shen; Weng-Im Leung; Jian-Qing Ruan; Song-Lin Li; Jacky Pui-Cheong Lei; Yi-Tao Wang; Ru Yan
Journal:  Chin Med       Date:  2013-11-23       Impact factor: 5.455

8.  Gypenoside Protects Cardiomyocytes against Ischemia-Reperfusion Injury via the Inhibition of Mitogen-Activated Protein Kinase Mediated Nuclear Factor Kappa B Pathway In Vitro and In Vivo.

Authors:  Haijie Yu; Liye Shi; Guoxian Qi; Shijie Zhao; Yuan Gao; Yuzhe Li
Journal:  Front Pharmacol       Date:  2016-06-01       Impact factor: 5.810

9.  Gynostemma pentaphyllum Attenuates the Progression of Nonalcoholic Fatty Liver Disease in Mice: A Biomedical Investigation Integrated with In Silico Assay.

Authors:  Ming Hong; Zhe Cai; Lei Song; Yongqiang Liu; Qi Wang; Xiangfei Feng
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-21       Impact factor: 2.629

10.  Gypenosides Altered Hepatic Bile Acids Homeostasis in Mice Treated with High Fat Diet.

Authors:  Yanliu Lu; Yimei Du; Lin Qin; Di Wu; Wei Wang; Lei Ling; Feifei Ma; Hua Ling; Li Yang; Changhong Wang; Zhengtao Wang; Xumei Zhou; Yuqi He
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.